Voyager Therapeutics, Inc. (VYGR) Total liabilities 2016–2025
Voyager Therapeutics, Inc. (VYGR) total liabilities at each fiscal year-end, per SEC filings.
$56.2MFY2025 · since FY2016: $53.6M → $56.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $56.2M | -39.8% |
| FY2024 | $93.3M | -18.9% |
| FY2023 | $115.0M | +14.6% |
| FY2022 | $100.3M | +1.6% |
| FY2021 | $98.8M | -7.9% |
| FY2020 | $107.3M | -58.0% |
| FY2019 | $255.2M | +95.5% |
| FY2018 | $130.6M | +159.0% |
| FY2017 | $50.4M | -6.0% |
| FY2016 | $53.6M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VYGR financial trends
VYGR RevenueVYGR Net incomeVYGR Net marginVYGR Gross profitVYGR Gross marginVYGR Operating incomeVYGR Operating marginVYGR Operating cash flowVYGR Free cash flowVYGR Capital expendituresVYGR Return on equityVYGR Stock buybacksVYGR Dividends paidVYGR Total assetsVYGR Shareholders’ equityVYGR overview →